-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Venture Capital
BIO Europe Spring 2012 – Opening Remarks
For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public market performance in the US vs other sectors Private funding environment. Drug pipeline deal volume. For a copy of the slides, they can be found here.
Inside BIO Industry Analysis
Leave a comment
Email This Post
Tags: BIO Europe, deals, Industry Analysis, opening remarks, orphan, Partnering, Partnering Stats, PowerPoint, PRIVATE BIOTECH, PUBLIC BIOTECH - Stats, PUBLIC BIOTECH - Stock performance, public sector research, Venture Capital, venture financing, venture funding
Tags: BIO Europe, deals, Industry Analysis, opening remarks, orphan, Partnering, Partnering Stats, PowerPoint, PRIVATE BIOTECH, PUBLIC BIOTECH - Stats, PUBLIC BIOTECH - Stock performance, public sector research, Venture Capital, venture financing, venture funding
Venture Capital increases in 2011, but…
The National Venture Capital Association (NVCA) has released their 4Q 2011 numbers for biotech venture financing in the US. The report echoes the global numbers already out from BioCentury and BioWorld – a boost in investment for 2011. The take away, however, is not the total amount, but 1) the drop in the total number of biotech deals, and 2) the drop in start-up, early-stage deals from 2010. The total number of deals near 447 was down Read More >
Multiple Assets Diversify the Deal
With a recent surge in pharma companies collaborating earlier on with small biotech companies, discovery stage partnering deals are becoming increasingly popular. Striking a discovery stage deal can be extremely beneficial for both parties in today’s environment – pharma gets to fill its ever elusive R&D pipeline as patent expirations loom, and the small biotech struggling to raise money to stay alive gets the capital infusion necessary to stay in play. Panelists in the “Broad Read More >
Medical Innovation at Risk
The National Venture Capital Association’s MedIC Coalition recently released a report showing U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investments towards Europe and Asia. The report, Vital Signs: The Threat to Investment in U.S. Medical Innovation and the Imperative of FDA Reform, strongly indicates that America’s medical innovation economy is in grave danger of losing its primary source of funding, Read More >
Policies that Benefit Start-Ups Grow the Bio-Economy
The United States remains the land of entrepreneurialism despite our lingering economic troubles. To maintain our nation’s global leadership and drive job growth, we must continue to create policies that encourage and reward innovation in growth industries — including biotechnology. Jeffrey Bussgang, a general partner at the venture capital firm Flybridge Capital Partners contributed an interesting piece to Fortune/CNN Money in which he points out that start-up companies – not small businesses – are the Read More >
